Korean J Med.  2008 May;74(5):506-514.

Clinical manifestations for diabetes mellitus in HIV-infected Koreans on highly active antiretroviral therapy

• Choi H
• Jeong SJ
• Lee HS
• Chin BS
• Choi SH
• Han SH
• Kim MS
• Kim CO
• Choi JY
• Song YG
• Kim JM

Abstract

BACKGROUND/AIMS: The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of HIV infection. However, the HAART regimens, and especially those including protease inhibitors (PIs), have been shown to cause diabetes mellitus. We evaluated the incidence and clinical manifestations of HIV-infected Koreans who received HAART and the risk factors for diabetes mellitus in those patients.
METHODS
We conducted a retrospective cohort study and a case-control study to evaluate the clinical manifestations, the incidence and the risk factors for diabetes mellitus in 215 HIV-infected patients who were on HAART at Yonsei University College of Medicine from 1991 to 2006.
RESULTS
215 patients were analyzed and the total duration of follow up was 1079 person-years. The incidences of diabetes mellitus and impaired fasting glucose were 1.39 case/100person-years and 6.02 case/100person-years. Most of the cases were non-obese type II diabetes and these patients showed insulin resistance and impaired beta cell function. On the risk factor analysis, the factors contributing to the development of diabetes were age, a decrease of the viral load and indinavir use.
CONCLUSIONS
In our study, the incidence of diabetes among Korean HIV-positive patients on HAART was 1.39case/100person-years. Age, a decrease of the viral load and indinavir use were the risk factors for development of diabetes mellitus.

Keyword

HIV; Acquired immunodeficiency syndrome; Diabetes mellitus; Antiretroviral therapy

MeSH Terms

Acquired Immunodeficiency Syndrome
Antiretroviral Therapy, Highly Active
Case-Control Studies
Cohort Studies
Diabetes Mellitus
Fasting
Follow-Up Studies
Glucose
HIV
HIV Infections
Humans
Incidence
Indinavir
Insulin Resistance
Protease Inhibitors
Retrospective Studies
Risk Factors
Viral Load
Glucose
Indinavir
Protease Inhibitors